Adult vaccinations as part of healthy ageing

Role of the Australian Technical Advisory Group on Immunisation (ATAGI)

Prof Ross Andrews
Chair ATAGI

ross.andrews@menzies.edu.au  atagi.secretariat@health.gov.au
Adult vaccinations as part of healthy ageing

Role of the Australian Technical Advisory Group on Immunisation (ATAGI)

Uptake  Safety  Effectiveness

Evidence-based technical advice on vaccine USE

www.immunise.health.gov.au
Adult vaccinations as part of healthy ageing

Role of the Australian Technical Advisory Group on Immunisation (ATAGI)

- Evidence-based technical advice on vaccine use
- Uptake
- Safety
- Effectiveness

ATAGI Terms of Reference

- Minister for Health
- PBAC
- Research funders
Adult vaccination, Australia
(potted history)

1986: TIV *Trivalent Influenza Vaccine recommended* for ≥65yrs + other RFs

1994: TIV *recommended* for Aboriginal & Torres Strait Islander adults ≥50yrs

1997: ATAGI established

1999: TIV *funded* ≥65yrs, Aboriginal & Torres Strait Islander adults ≥50yrs + other RFs

1999: 23vPPV *funded* Aboriginal & Torres Strait Islander adults ≥50yrs + 15-49yrs RFs

2005: 23vPPV *funded* ≥65yrs

2005 PBAC role established in NIP *(vaccine summary relevant to older adults)*

2008: Zoster vaccine *PBAC recommendation but no vaccine avail. for NIP consideration*

2010: TIV *NIP funded* for Aboriginal & Torres Strait Islander people ≥15yrs

2014: Zoster vaccine *PBAC recommendation Nov 2014, NIP funded Nov 2016 @ 70yrs + catch-up*

2015: QIV *PBAC recommendation July 2015 as cost-minimisation to TIV: NIP funded 2016*

2015: 13vPCV *PBAC recommendation July 2015 as cost-minimisation to 23vPPV for ≥65yrs, Indig.≥50yrs*
Adding a vaccine on the National Immunisation Program
(PBAC vaccine submission process)

Preparatory phase

- Annual meeting ATAGI + Industry
- ATAGI WP (working party) established
- Sponsor seeks TGA approval
- Sponsor requests ATAGI pre-PBAC submission advice

Pre-submission phase

- ATAGI pre-submission advice to Sponsor + PBAC
- Sponsor makes application to PBAC
- ATAGI post-sub. advice to Sponsor + PBAC
  (ATAGI Chair & WP Chair attend PBAC)

PBAC outcomes: www.pbs.gov.au
Trend by time period: Annual incidence of ICD-coded hospitalisation for influenza (any diagnosis) 2002-2013, by age group and time period
Influenza Vaccine Effectiveness: FluCAN

- 17 Australian hospitals
- Surveillance for severe flu
- VE based on case-test negative control design
  - Case: PCR confirmed flu
  - Control: Next test negative ILI
- Assumes flu vaccine has no effect on non-flu ILI
- VE=1-OR
  - Odds ratio adjusted for age group, comorbidities, pregnancy, Indigenous status

Cheng CDI 2015; 39(3): e355

FluCAN 2010-15
Immunisation uptake

Figure 1: Primary Health Network areas with the highest and lowest child immunisation rates, 2014–15

<table>
<thead>
<tr>
<th>All children</th>
<th>Aboriginal and Torres Strait Islander children</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 year</td>
<td></td>
</tr>
<tr>
<td>93.6% Highest</td>
<td>92.9% Highest</td>
</tr>
<tr>
<td>Murrumbidgee (NSW)</td>
<td>Australian Capital Territory</td>
</tr>
<tr>
<td>87.7% Lowest</td>
<td>75.2% Lowest</td>
</tr>
<tr>
<td>North Coast (NSW)</td>
<td>Perth South</td>
</tr>
<tr>
<td>2 years</td>
<td></td>
</tr>
<tr>
<td>92.3% Highest</td>
<td>90.4% Highest</td>
</tr>
<tr>
<td>Murrumbidgee (NSW)</td>
<td>South Western Sydney</td>
</tr>
<tr>
<td>86.7% Lowest</td>
<td>76.9% Lowest</td>
</tr>
<tr>
<td>North Coast (NSW)</td>
<td>Perth North</td>
</tr>
<tr>
<td>5 years</td>
<td></td>
</tr>
<tr>
<td>95.6% Highest</td>
<td>96.7% Highest</td>
</tr>
<tr>
<td>Murrumbidgee (NSW)/Western NSW</td>
<td>Western NSW</td>
</tr>
<tr>
<td>89.2% Lowest</td>
<td>86.5% Lowest</td>
</tr>
<tr>
<td>North Coast (NSW)</td>
<td>Perth South</td>
</tr>
</tbody>
</table>

Sources and references can be found in this report in 'About the data' (page 12) or in the Technical Note at www.myhealthycommunities.gov.au/publications

Visit www.myhealthycommunities.gov.au for more detailed results

65 years  ?? Highest  ?? Lowest  50 years  ?? Highest  ?? Lowest
Immunisation uptake

From: Australian Childhood Immunisation (ACIR)
To: Australian Immunisation (AIR)

Jan 2016:
ACIR expanded to include vaccines up to age 20 yrs

Sep 2016:
Whole of life immunisation register to be launched
Shingles / Herpes Zoster

- National Program commences 1 Nov 2016
  - Zostavax®, manufactured by Seqirus, formerly bioCSL
  - Protection against shingles (herpes zoster) and associated post-herpetic neuralgia (PHN)

- 70 year olds (~240,000 people / year)

- Catch-up program for 71-79 yo ceases 2021-22 (~1.4m people)

- Booster not yet determined
  - If required, vaccine recipients to be recalled using A.I.R
Zoster update

- Current wording
  Zostavax is contraindicated in persons with significant immunocompromise ..... 

Update coming.....online ~ Aug 2016

- More detail on specific immunosuppressive agents
  (disease modifying anti-rheumatic drugs, DMARDs)
First Conference of the Global NITAG Network

May 11-12, 2016
Fondation Mérieux, Veyrier-du-Lac, France

DRAFT REPORT
Thank you
Australian Government Vaccine Expenditure Trend 1996-2016 NIP

- Seven Point Plan
- Meningococcal
- Pneumococcal
- Human Papillomavirus
- End of Human Papillomavirus Catch-up program
- Hep B and Pneumococcal Catch-up Programs ceased
- No Jab No Pay and DTPs

2015-16 is estimated expenditure

Financial Years